No profile data available.
Upstream Bio, Inc. (UPB) is a healthcare company in the lung treatment pharmaceuticals industry, based in Waltham, United States, with about 52 full-time employees.
It reported revenue of $2.85 million for fiscal year 2025, up 20.4% from fiscal year 2024, and net income of -$143.44 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $773,000, down 17.5% from a year before. Its market capitalization was $1.50 billion as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.
Upstream Bio reported $2.85 million in revenue for fiscal year 2025, up 20.4% from $2.37 million in fiscal year 2024. In Q2 2026 revenue was $773,000.
$1.50 billion as of December 4, 2025.
Listed companies of a similar size in the same industry (lung treatment pharmaceuticals) include Vertex Pharmaceuticals Incorporated (VRTX), Innoviva, Inc. (INVA), Savara Inc. (SVRA), Gyre Therapeutics, Inc. (GYRE).